Logo image of WVE

WAVE LIFE SCIENCES LTD (WVE) Stock Fundamental Analysis

NASDAQ:WVE - Nasdaq - SG9999014716 - Common Stock - Currency: USD

6.585  +0.04 (+0.69%)

After market: 6.6597 +0.07 (+1.13%)

Fundamental Rating

3

Overall WVE gets a fundamental rating of 3 out of 10. We evaluated WVE against 198 industry peers in the Pharmaceuticals industry. While WVE seems to be doing ok healthwise, there are quite some concerns on its profitability. WVE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

WVE had negative earnings in the past year.
WVE had a negative operating cash flow in the past year.
WVE had negative earnings in each of the past 5 years.
In the past 5 years WVE always reported negative operating cash flow.
WVE Yearly Net Income VS EBIT VS OCF VS FCFWVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -27.54%, WVE perfoms like the industry average, outperforming 54.04% of the companies in the same industry.
WVE has a Return On Equity of -44.62%. This is comparable to the rest of the industry: WVE outperforms 56.06% of its industry peers.
Industry RankSector Rank
ROA -27.54%
ROE -44.62%
ROIC N/A
ROA(3y)-53%
ROA(5y)-54.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WVE Yearly ROA, ROE, ROICWVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

WVE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WVE Yearly Profit, Operating, Gross MarginsWVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

WVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for WVE has been increased compared to 1 year ago.
WVE has more shares outstanding than it did 5 years ago.
WVE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
WVE Yearly Shares OutstandingWVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
WVE Yearly Total Debt VS Total AssetsWVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 0.01, we must say that WVE is in the distress zone and has some risk of bankruptcy.
WVE has a Altman-Z score of 0.01. This is comparable to the rest of the industry: WVE outperforms 56.06% of its industry peers.
WVE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.01
ROIC/WACCN/A
WACC9.79%
WVE Yearly LT Debt VS Equity VS FCFWVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

WVE has a Current Ratio of 2.89. This indicates that WVE is financially healthy and has no problem in meeting its short term obligations.
WVE has a Current ratio (2.89) which is comparable to the rest of the industry.
A Quick Ratio of 2.89 indicates that WVE has no problem at all paying its short term obligations.
WVE's Quick ratio of 2.89 is in line compared to the rest of the industry. WVE outperforms 57.07% of its industry peers.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 2.89
WVE Yearly Current Assets VS Current LiabilitesWVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

WVE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.54%.
The Revenue has decreased by -4.42% in the past year.
Measured over the past years, WVE shows a very strong growth in Revenue. The Revenue has been growing by 46.63% on average per year.
EPS 1Y (TTM)-61.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.83%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y38.28%
Revenue growth 5Y46.63%
Sales Q2Q%-26.78%

3.2 Future

Based on estimates for the next years, WVE will show a very strong growth in Earnings Per Share. The EPS will grow by 22.46% on average per year.
WVE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 50.08% yearly.
EPS Next Y-26.92%
EPS Next 2Y-16.08%
EPS Next 3Y4.91%
EPS Next 5Y22.46%
Revenue Next Year31.24%
Revenue Next 2Y13.85%
Revenue Next 3Y45.83%
Revenue Next 5Y50.08%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
WVE Yearly Revenue VS EstimatesWVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
WVE Yearly EPS VS EstimatesWVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for WVE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for WVE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WVE Price Earnings VS Forward Price EarningsWVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WVE Per share dataWVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.08%
EPS Next 3Y4.91%

More info and screens

0

5. Dividend

5.1 Amount

WVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WAVE LIFE SCIENCES LTD

NASDAQ:WVE (5/9/2025, 8:27:50 PM)

After market: 6.6597 +0.07 (+1.13%)

6.585

+0.04 (+0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners83.58%
Inst Owner Change0.13%
Ins Owners0.5%
Ins Owner Change6.46%
Market Cap1.01B
Analysts83.53
Price Target21.93 (233.03%)
Short Float %9.12%
Short Ratio8.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)64.12%
Min EPS beat(2)-64.24%
Max EPS beat(2)192.48%
EPS beat(4)1
Avg EPS beat(4)24.36%
Min EPS beat(4)-64.24%
Max EPS beat(4)192.48%
EPS beat(8)4
Avg EPS beat(8)-32.16%
EPS beat(12)5
Avg EPS beat(12)-23.16%
EPS beat(16)6
Avg EPS beat(16)-17.53%
Revenue beat(2)1
Avg Revenue beat(2)25.46%
Min Revenue beat(2)-144.85%
Max Revenue beat(2)195.76%
Revenue beat(4)1
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-144.85%
Max Revenue beat(4)195.76%
Revenue beat(8)4
Avg Revenue beat(8)31.66%
Revenue beat(12)4
Avg Revenue beat(12)-5.92%
Revenue beat(16)5
Avg Revenue beat(16)-5.23%
PT rev (1m)-1.61%
PT rev (3m)0.56%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)11.56%
EPS NY rev (1m)-1.71%
EPS NY rev (3m)5.95%
Revenue NQ rev (1m)2.32%
Revenue NQ rev (3m)-4.47%
Revenue NY rev (1m)0.64%
Revenue NY rev (3m)-9.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.37
P/FCF N/A
P/OCF N/A
P/B 4.67
P/tB 4.67
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-1.06
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0.7
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.54%
ROE -44.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53%
ROA(5y)-54.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.08%
Cap/Sales 0.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 2.89
Altman-Z 0.01
F-Score2
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)22.36%
Cap/Depr(5y)18.22%
Cap/Sales(3y)13.04%
Cap/Sales(5y)9.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.83%
EPS Next Y-26.92%
EPS Next 2Y-16.08%
EPS Next 3Y4.91%
EPS Next 5Y22.46%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y38.28%
Revenue growth 5Y46.63%
Sales Q2Q%-26.78%
Revenue Next Year31.24%
Revenue Next 2Y13.85%
Revenue Next 3Y45.83%
Revenue Next 5Y50.08%
EBIT growth 1Y-62.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.97%
EBIT Next 3Y-16.01%
EBIT Next 5YN/A
FCF growth 1Y-639.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-677.24%
OCF growth 3YN/A
OCF growth 5YN/A